| Display title | Chemistry:Istiratumab |
| Default sort key | Istiratumab |
| Page length (in bytes) | 2,545 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 329139 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>John Stpola |
| Date of page creation | 01:55, 27 June 2023 |
| Latest editor | imported>John Stpola |
| Date of latest edit | 01:55, 27 June 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.
It is in development by Merrimack Pharmaceuticals and was awarded orphan drug status for pancreatic cancer. |
